MedImmune Licenses Flu Vaccine Technology To Novartis
MedImmune, Inc. (Gaithersburg, MD, www.medimmune.com), has licensed its proprietary reverse genetics intellectual property to Novartis (Basel, Switzerland, www.novartisvaccines.com), to support the development and construction of new vaccine strains to produce inactivated human seasonal, pre-pandemic, and pandemic influenza vaccines.
MedImmune, Inc. (Gaithersburg, MD, www.medimmune.com), has licensed its proprietary reverse genetics intellectual property to Novartis (Basel, Switzerland, www.novartisvaccines.com), to support the development and construction of new vaccine strains to produce inactivated human seasonal, pre-pandemic, and pandemic influenza vaccines. By using reverse genetics, viruses like influenza can be generated from segments of DNA. For prospective pandemic influenza vaccines, reverse genetics can be a useful technology because the process does not require manufacturers to work directly with potentially highly infectious pandemic strains, such as H5N1, rather only segments of the virus's genome.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
